GlassScriptPhysician profile
Akshay S Thomas
NPI 1528324662
$108,370.76
in general payments reported to CMS, 2019-2025
23 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,766 · 2020: $8,598 · 2021: $18K · 2022: $26K · 2023: $20K · 2024: $20K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $4,329 · Travel and Lodging: $3,657 · Honoraria: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,502.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,580.00 |
| Food and Beverage | $4,328.68 |
| Travel and Lodging | $3,657.49 |
| Honoraria | $3,087.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46,494.89 | 2019-2025 | Vabysmo, Susvimo |
| Carl Zeiss Meditec, INC. | $11,524.70 | 2020-2021 | |
| Alimera Sciences, INC. | $10,941.57 | 2019-2024 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $7,918.24 | 2022-2025 | Xipere, Stellaris |
| Allergan, INC. | $6,890.69 | 2019-2021 | |
| Eyepoint US, INC. | $5,830.58 | 2020-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,360.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $5,073.49 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $2,982.14 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $2,090.11 | 2025 | Yutiq, Purified Cortrophin Gel |
| Abbvie INC. | $963.09 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $442.07 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $425.58 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $410.60 | 2022-2025 | Syfovre |
| Biogen, INC. | $265.81 | 2022-2024 | Byooviz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $166.45 | 2024 | Tissueblue, Eva, Combined Machine |
| Coherus Oncology, INC. | $159.36 | 2022-2023 | |
| Neurotech Pharmaceuticals, INC. | $125.22 | 2025 | |
| Ocular Therapeutix, INC. | $121.21 | 2024-2025 | Dextenza |
| Genentech, INC. | $89.68 | 2024 | Vabysmo |
| Harrow Eye, LLC | $60.83 | 2025 | Triesence, Iheezo |
| Mallinckrodt Enterprises LLC | $17.65 | 2019 | |
| Amgen INC. | $15.83 | 2025 | Pavblu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshay Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.